HHS Guidance To Clarify Which Adverse Events Researchers Need To Report
This article was originally published in The Gray Sheet
Executive Summary
A final HHS guidance due in December will clarify which adverse events occurring in clinical trials must be reported to authorities
You may also be interested in...
HHS Guidance Aims To Curb Overreporting Of Clinical-Trial Adverse Events
A final HHS 1guidance explains that only a small subset of adverse events occurring in HHS-funded clinical research need be reported
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”